IRVINE, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Endo International plc (“Endo” or the “Company”) (Nasdaq: ENDP ). Investors who purchased or otherwise acquired Endo shares from November 30, 2012 through July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by October 17, 2017, the lead plaintiff motion deadline.
If you purchased Endo shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834 , or by e-mail at joon@khanglaw.com .
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Endo made false and/or misleading statements, and/or failed to disclose that: Reformulated Opana was not resistant to crushing; that Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; that Reformulated Opana was contributing to an opioid public health crisis; and that Endo would ultimately remove Reformulated Opana from the market. Following this news, shares of Endo dropped in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone: (949) 419-3834 , or by e-mail at joon@khanglaw.com .
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact
Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 joon@khanglaw.com
